NASDAQ:IGMS

IGM Biosciences Competitors

$68.49
-11.21 (-14.07 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$68.00
Now: $68.49
$80.46
50-Day Range
$71.56
MA: $84.40
$95.54
52-Week Range
$41.41
Now: $68.49
$133.00
Volume308,429 shs
Average Volume196,716 shs
Market Capitalization$2.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta-1.12

Competitors

IGM Biosciences (NASDAQ:IGMS) Vs. BBIO, RARE, GWPH, ASND, ARWR, and TGTX

Should you be buying IGMS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to IGM Biosciences, including BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), and TG Therapeutics (TGTX).

BridgeBio Pharma (NASDAQ:BBIO) and IGM Biosciences (NASDAQ:IGMS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

95.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by company insiders. Comparatively, 79.3% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for BridgeBio Pharma and IGM Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BridgeBio Pharma01902.90
IGM Biosciences01602.86

BridgeBio Pharma currently has a consensus target price of $72.8889, indicating a potential upside of 33.77%. IGM Biosciences has a consensus target price of $98.8750, indicating a potential upside of 44.36%. Given IGM Biosciences' higher probable upside, analysts plainly believe IGM Biosciences is more favorable than BridgeBio Pharma.

Valuation & Earnings

This table compares BridgeBio Pharma and IGM Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$40.56 million200.11$-260,590,000.00($2.48)-21.97
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27

IGM Biosciences has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BridgeBio Pharma and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BridgeBio PharmaN/A-109.88%-48.54%
IGM BiosciencesN/A-33.30%-30.28%

Risk and Volatility

BridgeBio Pharma has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500.

Summary

BridgeBio Pharma beats IGM Biosciences on 7 of the 12 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and IGM Biosciences (NASDAQ:IGMS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Ultragenyx Pharmaceutical and IGM Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
IGM Biosciences01602.86

Ultragenyx Pharmaceutical currently has a consensus target price of $131.20, indicating a potential upside of 26.79%. IGM Biosciences has a consensus target price of $98.8750, indicating a potential upside of 44.36%. Given IGM Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe IGM Biosciences is more favorable than Ultragenyx Pharmaceutical.

Risk and Volatility

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500.

Insider & Institutional Ownership

47.6% of IGM Biosciences shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 79.3% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Ultragenyx Pharmaceutical and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
IGM BiosciencesN/A-33.30%-30.28%

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and IGM Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million66.80$-402,730,000.00($7.36)-14.06
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27

IGM Biosciences has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. IGM Biosciences is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats Ultragenyx Pharmaceutical on 8 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and GW Pharmaceuticals (NASDAQ:GWPH) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IGM Biosciences and GW Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
GW Pharmaceuticals010402.29

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. GW Pharmaceuticals has a consensus price target of $204.0909, indicating a potential downside of 6.35%. Given IGM Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe IGM Biosciences is more favorable than GW Pharmaceuticals.

Volatility & Risk

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Valuation and Earnings

This table compares IGM Biosciences and GW Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
GW Pharmaceuticals$311.33 million21.94$-9,020,000.00($0.24)-908.04

GW Pharmaceuticals has higher revenue and earnings than IGM Biosciences. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

GW Pharmaceuticals beats IGM Biosciences on 7 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IGM Biosciences and Ascendis Pharma A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
Ascendis Pharma A/S011102.92

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. Ascendis Pharma A/S has a consensus price target of $187.6667, indicating a potential upside of 49.40%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than IGM Biosciences.

Volatility & Risk

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Valuation and Earnings

This table compares IGM Biosciences and Ascendis Pharma A/S's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
Ascendis Pharma A/S$14.98 million450.70$-244,180,000.00($5.25)-23.93

IGM Biosciences has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats Ascendis Pharma A/S on 7 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Volatility & Risk

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IGM Biosciences and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
Arrowhead Pharmaceuticals021002.83

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. Arrowhead Pharmaceuticals has a consensus price target of $85.3077, indicating a potential upside of 37.26%. Given IGM Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe IGM Biosciences is more favorable than Arrowhead Pharmaceuticals.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Valuation and Earnings

This table compares IGM Biosciences and Arrowhead Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
Arrowhead Pharmaceuticals$87.99 million73.31$-84,550,000.00($0.84)-73.99

IGM Biosciences has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Arrowhead Pharmaceuticals beats IGM Biosciences on 7 of the 13 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

IGM Biosciences has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for IGM Biosciences and TG Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
TG Therapeutics00503.00

IGM Biosciences presently has a consensus price target of $98.8750, indicating a potential upside of 44.36%. TG Therapeutics has a consensus price target of $64.00, indicating a potential upside of 42.89%. Given IGM Biosciences' higher probable upside, analysts clearly believe IGM Biosciences is more favorable than TG Therapeutics.

Institutional and Insider Ownership

47.6% of IGM Biosciences shares are held by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are held by institutional investors. 79.3% of IGM Biosciences shares are held by insiders. Comparatively, 13.2% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares IGM Biosciences and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
TG Therapeutics-151,798.69%-223.96%-108.08%

Valuation & Earnings

This table compares IGM Biosciences and TG Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27
TG Therapeutics$150,000.0041,978.98$-172,870,000.00($1.83)-24.48

IGM Biosciences has higher earnings, but lower revenue than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

IGM Biosciences beats TG Therapeutics on 7 of the 13 factors compared between the two stocks.


IGM Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.49-6.7%$8.12 billion$40.56 million-15.98Analyst Report
Gap Down
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$103.48-3.0%$6.93 billion$103.71 million-23.57News Coverage
Gap Down
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.93-0.0%$6.83 billion$311.33 million-126.70Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$125.61-3.1%$6.75 billion$14.98 million-15.30Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.15-2.5%$6.45 billion$87.99 million-73.99News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.79-4.3%$6.30 billion$150,000.00-21.13News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36-0.8%$5.97 billion$1.12 billion88.25
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$70.54-1.3%$5.60 billion$380.83 million-9.02
Allakos logo
ALLK
Allakos
1.7$105.00-2.9%$5.58 billionN/A-38.32Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.16-0.1%$5.46 billion$66.51 million17.37
Perrigo logo
PRGO
Perrigo
2.5$40.53-0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.5$73.90-4.1%$5.17 billion$85.54 million0.00Insider Selling
Gap Down
Galapagos logo
GLPG
Galapagos
1.3$77.81-0.1%$5.10 billion$1.00 billion-11.79
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
1.8$56.51-0.5%$4.68 billionN/A0.00Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.61-0.7%$4.47 billion$6.87 million-7.40Analyst Report
Analyst Revision
News Coverage
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$69.39-2.2%$4.31 billionN/A-5.66Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.24-2.3%$4.26 billion$204.89 million-36.55News Coverage
Gap Up
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35-1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29-0.3%$4.00 billion$806.43 million-9.39
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$78.95-3.9%$3.87 billionN/A-22.49Analyst Report
News Coverage
Gap Down
LEGN
Legend Biotech
1.2$28.45-6.5%$3.76 billion$64.39 million0.00Gap Down
I-Mab logo
IMAB
I-Mab
1.4$51.65-2.3%$3.72 billion$4.31 million-1.79Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.77-0.3%$3.67 billion$117.91 million-10.70News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41-0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63-3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.60-1.4%$3.35 billion$306.98 million-6.81
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.56-0.0%$3.34 billionN/A-5.60News Coverage
Insmed logo
INSM
Insmed
1.2$31.70-2.0%$3.27 billion$136.47 million-12.19Analyst Upgrade
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.39-1.4%$3.26 billion$339.08 million-11.85Analyst Downgrade
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$88.42-7.3%$3.20 billion$26.52 million-7.79Unusual Options Activity
Gap Down
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$116.91-0.9%$3.16 billionN/A-58.16News Coverage
Arvinas logo
ARVN
Arvinas
1.5$63.49-1.5%$3.10 billion$42.98 million-24.80Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.02-0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25-0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.36-0.8%$2.94 billion$80.43 million106.48Analyst Report
Organogenesis logo
ORGO
Organogenesis
1.0$22.84-4.9%$2.92 billion$260.98 million-380.67Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.18-2.2%$2.80 billion$901.90 million-23.22
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.83-0.2%$2.79 billion$644.77 million-10.39Analyst Upgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68-1.0%$2.66 billion$306.49 million25.48Insider Selling
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.69-0.6%$2.56 billion$60,000.00-9.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$63.77-13.2%$2.56 billionN/A0.00Analyst Report
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44-1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.77-1.1%$2.53 billion$2.11 million-8.82Analyst Upgrade
News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$43.81-1.4%$2.52 billion$25 million-8.76Insider Selling
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$39.41-8.7%$2.43 billionN/A-21.65News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19-0.9%$2.43 billion$182.24 million-7.99News Coverage
Cryoport logo
CYRX
Cryoport
1.9$52.29-3.1%$2.38 billion$33.94 million-90.16Insider Selling
News Coverage
Gap Down
Xencor logo
XNCR
Xencor
1.2$40.47-2.9%$2.35 billion$156.70 million-28.91News Coverage
Gap Down
Amarin logo
AMRN
Amarin
1.6$5.93-1.2%$2.33 billion$429.76 million-118.58
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.